1. Baker, S.G., and Kramer, B.S. (2003) A perfect correlate does not a surrogate make. BMC Med. Res. Methodol.3, 16.
2. Batchelor, T., Stanley, K., and Andersen, J. (2001) Clinical trials in neurooncology. Curr. Opin. Neurol.14, 689-694.
3. Begg, C.B., and Leung, D.H.Y. (2000) On the use of surrogate end points in randomized trials. J. R. Stat. Soc. A163(pt. 1), 15-28.
4. Brada, M., and Yung, W.K.A. (2000) Clinical trial end points in malignant glioma: Need for effective trial design strategy. Semin. Oncol.27(suppl. 6), 11-19.
5. Buckner, J.C., Brown, L.D., Cascino, T.L., Gerstner, J.B., Krook, J.E., Westberg, M.W., Wiesenfeld, M., O'Fallon, J.R., and Scheithauer, B. (1990) Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J. Neurooncol.9, 249-254.